|Articles|October 20, 2022

Addressing Antibiotic Prescribing Inequities

Evidence demonstrates how these therapies are prescribed around patients’ races.


It is well-known that the COVID-19 pandemic highlighted the health inequities experienced amongst the different races in the United States. For example, there been studies pointing to vaccine inequities ranging from people of color not being involved in COVID-19 vaccine trials to issues of access for these vaccines.

These inequities expand further into medical care including antibiotic prescribing practices explains Zanthia Wiley, MD associate professor of Medicine Emory University Atlanta, GA. She is serving in a number of capacities at this year’s IDWeek 2022 including acting as a moderator and giving a presentation, “Health Equity Considerations in Antibiotic Prescribing.”

In her presentation, she lays out these inequities. According to her research, both Hispanics and Black people are prescribed less antibiotics than their White counterparts. Wiley makes the distinction that its not about giving more antibiotics to people of color, but rather understanding there are these differences and account for them.

“What we would hope for is not that Blacks and Hispanics would receive more antibiotics than they currently are; because what we know is most antibiotics prescribed, especially outpatients, are prescribed inappropriately,” Wiley said. “So, it’s identifying and recognizing that we have these inequities and figuring out what we are going to do to move forward to eliminate inequities.”

Wiley spoke to Contagion further about these inequities and some of the strategies to address them.


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
ID Week Highlights Part 1
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.